Collaborative R&D with DM Bio, a company we established with Dong-A Socio Holdings in Korea.
DM Bio has established a commercial scale manufacturing technologies, which leads to contract manufacturing in the future.
DMB 3111 (trastuzumab)
Biosimilar of Herceptin, an anti-tumor agent.
Phase I trial completed in Japan.
DM Bio licensed development and sales rights in Europe and Russia to Richter Co., Hungarian company.
DMB 3113 (adalimumab)
Biosimilar of Humira, a fully human anti-TNF-α monoclonal antibody.
Phase I trial started in Japan.
We will invest in the fields in which we have a high expertise and promote the R&D effectively.
Progressed in two biosimilar projects.
Collaborative R&D with DM Bio, a company we established with Dong-A Socio Holdings in Korea.
DM Bio has established a commercial scale manufacturing technologies, which leads to contract manufacturing in the future.
DMB 3111 (trastuzumab)
Biosimilar of Herceptin, an anti-tumor agent.
Phase I trial completed in Japan.
DM Bio licensed development and sales rights in Europe and Russia to Richter Co., Hungarian company.
DMB 3113 (adalimumab)Biosimilar of Humira, a fully human anti-TNF-α monoclonal antibody.
Phase I trial started in Japan.
We will invest in the fields in which we have a high expertise and promote the R&D effectively.